




Edition: BP 2025 (Ph. Eur. 11.6 update)

Flunarizine Dihydrochloride



[General Notices](#)

(Ph. Eur. monograph 1722)



$C_{26}H_{28}Cl_2F_2N_2$ 477.4 30484-77-6

Action and use

Calcium channel blocker.

Ph Eur

DEFINITION

1-[Bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine dihydrochloride.

Content

99.0 per cent to 101.5 per cent (dried substance).

CHARACTERS

Appearance

White or almost white powder, hygroscopic.

Solubility

Slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION

A. Infrared absorption spectrophotometry ([2.2.24](#)).

Comparison [flunarizine dihydrochloride CRS](#).

B. Dissolve 25 mg in 2 mL of [methanol R](#) and add 0.5 mL of [water R](#). The solution gives reaction (a) of chlorides ([2.3.1](#)).

TESTS

Related substances

Liquid chromatography ([2.2.29](#)). *Prepare the solutions immediately before use and protect from light.*

Test solution Dissolve 0.100 g of the substance to be examined in [methanol R](#) and dilute to 10.0 mL with the same solvent.

Reference solution (a) Dissolve 10 mg of [flunarizine for system suitability CRS](#) (containing impurities B and C) in [methanol R](#) and dilute to 1 mL with the same solvent.

Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with [methanol R](#). Dilute 1.0 mL of this solution to 10.0 mL with [methanol R](#).

Column:

— size: $l = 0.10$ m, $\varnothing = 4.6$ mm;

— stationary phase: [base-deactivated end-capped octadecylsilyl silica gel for chromatography R](#) (3 μ m).

Mobile phase:

— mobile phase A: solution containing 23.8 g/L of [tetrabutylammonium hydrogen sulfate R](#) and 7 g/L of [ammonium acetate R](#);

— *mobile phase B*: [acetonitrile for chromatography R](#);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 12	80 → 40	20 → 60
12 - 15	40	60

Flow rate 1.5 mL/min.

Detection Spectrophotometer at 230 nm.

Injection 10 µL.

Identification of impurities Use the chromatogram supplied with [flunarizine for system suitability CRS](#) and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities B and C.

Relative retention With reference to flunarizine (retention time = about 8 min): impurity B = about 0.93; impurity C = about 0.96.

System suitability Reference solution (a):

— [peak-to-valley ratio](#): minimum 1.5, where H_p = height above the baseline of the peak due to impurity C and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to flunarizine.

Calculation of percentage contents:

— for each impurity, use the concentration of flunarizine dihydrochloride in reference solution (b).

Limits:

- *impurity B*: maximum 0.3 per cent;
- *unspecified impurities*: for each impurity, maximum 0.10 per cent;
- *total*: maximum 0.5 per cent;
- *reporting threshold*: 0.05 per cent.

[Loss on drying \(2.2.32\)](#)

Maximum 5.0 per cent, determined on 1.000 g by drying in an oven at 105 °C for 4 h.

[Sulfated ash \(2.4.14\)](#)

Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.

ASSAY

Dissolve 0.200 g in 70 mL of [ethanol \(96 per cent\) R](#). Carry out a potentiometric titration ([2.2.20](#)), using [0.1 M sodium hydroxide](#). Read the volume added at the second point of inflexion. Carry out a blank titration.

1 mL of [0.1 M sodium hydroxide](#) is equivalent to 23.87 mg of $C_{26}H_{28}Cl_2F_2N_2$.


STORAGE

In an airtight container, protected from light.


IMPURITIES

Specified impurities B.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph [Substances for pharmaceutical use \(2034\)](#). It is therefore not necessary to identify these impurities for demonstration of compliance. See also [5.10. Control of impurities in substances for pharmaceutical use](#)) A, C, D.




A. 1-[bis(4-fluorophenyl)methyl]piperazine,



B. 1-[(*RS*)-(4-fluorophenyl)phenylmethyl]-4-[(*2E*)-3-phenylprop-2-en-1-yl]piperazine,



C. 1-[(*RS*)-(2-fluorophenyl)(4-fluorophenyl)methyl]-4-[(*2E*)-3-phenylprop-2-en-1-yl]piperazine,



D. 1-[bis(4-fluorophenyl)methyl]-4-[(*2Z*)-3-phenylprop-2-en-1-yl]piperazine.

Ph Eur